EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ezetimibe Enhances Lipid Droplet and Mitochondria Contact Formation, Improving Fatty Acid Transfer and Reducing Lipotoxicity in Alport Syndrome Podocytes

Jin-Ju Kim iD, Eun-Jeong Yang iD, Judith Molina David, Sunjoo Cho, Maria Ficarella, Nils Pape, Josephin Elizabeth Schiffer, Rachel Njeim iD, Stephanie S Kim iD, Claudia Lo Re, Antonio Fontanella, Maria Kaber und 3 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252313134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jin-Ju Kim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Hauptthemen laut MEDLINE: Podocytes, Nephritis, Hereditary, Mitochondria, Ezetimibe. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitochondrial dysfunction is a critical factor in the pathogenesis of Alport syndrome (AS), contributing to podocyte injury and disease progression. Ezetimibe, a lipid-lowering drug, is known to inhibit cholesterol and fatty acid uptake and to reduce triglyceride content in the kidney cortex of mice with AS. However, its effects on lipid droplet (LD) utilization by mitochondria have not been explored. Transmission electron microscopy (TEM) and mitochondrial functional assays (ATP production, mitochondrial membrane potential, and citrate synthase activity) were used to investigate the impact of ezetimibe on LD–mitochondria contact formation and mitochondrial function in Col4a3KO (AS) and wildtype (WT) podocytes. TEM analysis revealed significant mitochondrial abnormalities in AS podocytes, including swollen mitochondria and reduced cristae density, while mitochondrial function assays showed decreased ATP production and lowered mitochondrial membrane potential. AS podocytes also demonstrated a higher content of LD but with reduced LD–mitochondria contact sites. Ezetimibe treatment significantly increased the number of LD–mitochondria contact sites, enhanced fatty acid transfer efficiency, and reduced intracellular lipid accumulation. These changes were associated with a marked reduction in the markers of lipotoxicity, such as apoptosis and oxidative stress. Mitochondrial function was significantly improved, evidenced by increased basal respiration, ATP production, maximal respiration capacity, and the restoration of mitochondrial membrane potential. Additionally, mitochondrial swelling was significantly reduced in ezetimibe-treated AS podocytes. Our findings reveal a novel role for ezetimibe in enhancing LD–mitochondria contact formation, leading to more efficient fatty acid transfer, reduced lipotoxicity, and improved mitochondrial function in AS podocytes. These results suggest that ezetimibe could be a promising therapeutic agent for treating mitochondrial dysfunction and lipid metabolism abnormalities in AS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PodocytesNephritis, HereditaryMitochondriaEzetimibeFatty AcidsLipid DropletsMembrane Potential, MitochondrialAnimalsMiceLipid MetabolismOxidative StressCollagen Type IVAnticholesteremic AgentsApoptosis

Stichwörter der Autor:innen

Alport syndrome podocytesfatty acidlipid dropletlipotoxicity

Substanzen

EzetimibeFatty AcidsCollagen Type IVAnticholesteremic Agents

Autor:innen und Institutionen

  • Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
  • Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, A.O.U "G. Martino", University of Messina, 98122 Messina, Italy.

ORCID-Profile: Jin-Ju Kim, Eun-Jeong Yang, Rachel Njeim, Stephanie S Kim, Sandra Merscher

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • NCATS NIH HHS
  • NIH/NIDDK
  • NRF
  • NIH
  • Boehringer Ingelheim
  • Katz family

Zitieren

APA

Kim, J. J., Yang, E. J., Molina David, J., Cho, S., Ficarella, M., Pape, N., Schiffer, J. E., Njeim, R., Kim, S. S., Lo Re, C., Fontanella, A., Kaber, M., Sloan, A., Merscher, S., & Fornoni, A. (2024). Ezetimibe Enhances Lipid Droplet and Mitochondria Contact Formation, Improving Fatty Acid Transfer and Reducing Lipotoxicity in Alport Syndrome Podocytes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252313134

Vancouver

Kim JJ, Yang EJ, Molina David J, Cho S, Ficarella M, Pape N, et al. Ezetimibe Enhances Lipid Droplet and Mitochondria Contact Formation, Improving Fatty Acid Transfer and Reducing Lipotoxicity in Alport Syndrome Podocytes. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252313134

BibTeX
@article{Kim2024,
  author = {Kim, Jin-Ju and Yang, Eun-Jeong and Molina David, Judith and Cho, Sunjoo and Ficarella, Maria and Pape, Nils and Schiffer, Josephin Elizabeth and Njeim, Rachel and Kim, Stephanie S and Lo Re, Claudia and Fontanella, Antonio and Kaber, Maria and Sloan, Alexis and Merscher, Sandra and Fornoni, Alessia},
  title = {Ezetimibe Enhances Lipid Droplet and Mitochondria Contact Formation, Improving Fatty Acid Transfer and Reducing Lipotoxicity in Alport Syndrome Podocytes},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252313134}
}
Kostenlos starten →